Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma

  • Research Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Myxofibrosarcoma (MFS) is an aggressive sarcoma that requires novel therapeutic approaches to improve its clinical outcome. Cell lines are a valuable tool for pre-clinical research; however, there is a lack of patient-derived cell lines of MFS available from public cell banks. This study aimed to develop a patient-derived cell line of MFS. A cell line designated NCC-MFS1-C1 was established from the primary tumor tissue of an 82-year-old male patient with MFS. The short tandem repeat pattern of NCC-MFS1-C1 cells was identical to that of the original tumor, but distinct from that of any other cell lines in public cell banks. NCC-MFS1-C1 cells were maintained as a monolayer culture for over 20 passages in 19 months; the cells exhibited spindle-like morphology, continuous growth, and ability for spheroid formation and invasion. Genomic assay showed that NCC-MFS1-C1 cells had gain and loss of genetic loci. Proteomic profiling revealed that the original tumor and the derived NCC-MFS1-C1 cells had similar, but distinct protein expression patterns. Screening of anti-cancer drugs in NCC-MFS1-C1 cells identified five candidate drugs for MFS. In conclusion, we established a novel MFS cell line, NCC-MFS1-C1, which could be used to study tumor development and effects of anti-cancer drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Fletcher CDM, Bridge JA, Hogendoorn P, Mertens F. WHO classification of tumours of soft tissue and bone. Fourth edn. Geneva: WHO Press; 2013.

    Google Scholar 

  2. Haglund KE, Raut CP, Nascimento AF, Wang Q, George S, Baldini EH. Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma. Int J Radiat Oncol Biol Phys. 2012;82:361–7.

    Article  PubMed  Google Scholar 

  3. Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720–5.

    Article  PubMed  Google Scholar 

  4. Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996;20:391–405.

    Article  CAS  PubMed  Google Scholar 

  5. Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta pathologica, microbiologica, et immunologica Scandinavica Supplement. 1983; 282:1–40.

  6. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977;39:1672–85.

    Article  CAS  PubMed  Google Scholar 

  7. Willems SM, Debiec-Rychter M, Szuhai K, Hogendoorn PC, Sciot R. Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model. Mod Pathol. 2006;19:407–16.

    Article  PubMed  Google Scholar 

  8. Lin CN, Chou SC, Li CF, et al. Prognostic factors of myxofibrosarcomas: implications of margin status, tumor necrosis, and mitotic rate on survival. J Surg Oncol. 2006;93:294–303.

    Article  PubMed  Google Scholar 

  9. Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer. Cell. 2016;166:740–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Kawashima H, Ogose A, Gu W, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28–35.

    Article  CAS  PubMed  Google Scholar 

  12. Huang HY, Wu WR, Wang YH, et al. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Clin Cancer Res. 2013;19:2861–72.

    Article  CAS  PubMed  Google Scholar 

  13. Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Salawu A, Fernando M, Hughes D, et al. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer. 2016;115:1058–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lohberger B, Stuendl N, Leithner A, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Scientific reports. 2017;7:44700.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Willems SM, Mohseny AB, Balog C, et al. Cellular/intramuscular myxoma and grade I myxofibrosarcoma are characterized by distinct genetic alterations and specific composition of their extracellular matrix. J Cell Mol Med. 2009;13:1291–301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Willems SM, van Remoortere A, van Zeijl R, Deelder AM, McDonnell LA, Hogendoorn PC. Imaging mass spectrometry of myxoid sarcomas identifies proteins and lipids specific to tumour type and grade, and reveals biochemical intratumour heterogeneity. J Pathol. 2010;222:400–9.

    Article  CAS  PubMed  Google Scholar 

  19. Jones EA, van Remoortere A, van Zeijl RJ, et al. Multiple statistical analysis techniques corroborate intratumor heterogeneity in imaging mass spectrometry datasets of myxofibrosarcoma. PLoS One. 2011;6:e24913.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Workgroup ATCCSDO. Cell line misidentification: the beginning of the end. Nat Rev Cancer. 2010;10:441–8.

    Article  CAS  Google Scholar 

  21. Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510–9.

    Article  CAS  PubMed  Google Scholar 

  22. Capes-Davis A, Dirks W, MacLeod R, Uphoff C. Quality matters: cell lines and their use in research. GIT Lab J Eur. 2014;17:12–3.

    Google Scholar 

  23. Kondo T, Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc. 2007;1:2940–56.

    Article  CAS  Google Scholar 

  24. Wisniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009;6:359–62.

    Article  CAS  PubMed  Google Scholar 

  25. Baehrecke EH, Dang N, Babaria K, Shneiderman B. Visualization and analysis of microarray and gene ontology data with treemaps. BMC Bioinformatics. 2004;5:84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126.

    Article  CAS  PubMed  Google Scholar 

  27. Arai K, Sakamoto R, Kubota D, Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics. 2013;13:2351–60.

    Article  CAS  PubMed  Google Scholar 

  28. Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017.

Download references

Acknowledgements

We thank Drs. M. Endo, Y. Minami, K. Shimizu, T. Mori, T. Uehara, M. Sugawara, Y. Araki, and Ms. R. Nakano of the Division of Musculoskeletal Oncology, National Cancer Center Hospital for sampling tumor tissue specimens from surgically resected materials. Fundamental Innovative Oncology Core at the National Cancer Center provided support for the SNP array experiment. We would like to thank Editage (http://www.editage.jp) for English language editing and constructive comments on the manuscript.

Funding

This study was funded by the National Cancer Center Research and Development Fund (26-A-9 and 29-A-2).

Author information

Authors and Affiliations

  1. Department of Innovative Seeds Evaluation, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Fusako Kito, Rieko Oyama, Marimu Sakumoto & Tadashi Kondo

  2. Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Kumiko Shiozawa, Zhiwei Qiao & Tadashi Kondo

  3. Division of Musculoskeletal Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Shunichi Toki & Akira Kawai

  4. Pathology and Clinical Laboratory Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Akihiko Yoshida

Authors
  1. Fusako Kito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rieko Oyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marimu Sakumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kumiko Shiozawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiwei Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shunichi Toki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Akihiko Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Akira Kawai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tadashi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadashi Kondo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kito, F., Oyama, R., Sakumoto, M. et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Human Cell 32, 214–222 (2019). https://doi.org/10.1007/s13577-018-00233-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-018-00233-1

Keywords

Search

Navigation